@article {8070,
	title = {Treatment of Waldenstrom{\textquoteright}s macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone},
	journal = {Seminars in Oncology},
	volume = {30},
	year = {2003},
	note = {Cited By :51Export Date: 21 February 2017},
	month = {2003},
	pages = {265 - 269},
	abstract = {To evaluate the activity of thalidomide in Waldenstrom{\textquoteright}s macroglobulinemia (WM), 20 patients were treated on a dose schedule that escalated from 200 mg/d to 600 mg/d. On an intention-to-treat basis, five (25\%) patients achieved a partial response, which was noted within 3 months of treatment. Adverse effects were common and prevented dose escalation of thalidomide in 75\% of patients and led to premature discontinuation of treatment in 35\%. We subsequently evaluated the oral combination of clarithromycin (500 mg twice per day), low-dose thalidomide (200 mg once daily), and dexamethasone (40 mg once per week). Our preliminary analysis on 12 previously treated patients indicate activity of this regimen in WM: three patients achieved a partial response and two patients demonstrated monoclonal protein reduction of greater than 25\%. This combination was associated with a variety of side effects due not only to thalidomide, but also to corticosteroids and to clarithromycin. Our preliminary data indicate that this combination may be a useful salvage regimen for some patients with heavily pretreated macroglobulinemia. {\textcopyright} 2003 Elsevier Inc. All rights reserved.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037397379\&doi=10.1053\%2fsonc.2003.50079\&partnerID=40\&md5=bec3f34f2d55a00032d51bcf8e7989ce},
	author = {Dimopoulos, M.A. and Tsatalas, C. and Zomas, A. and Hamilos, G. and Panayiotidis, P. and Margaritis, D. and Matsouka, C. and Economopoulos, T. and Anagnostopoulos, N.}
}
